Most Recent
Celebrity surgeon appeals loss in defamation case against Nine
Orthopaedic surgeon Dr Munjed Al Muderis has appealed his loss in a defamation case against Fairfax and its owner Nine, after a judge found media reports of unethical and profit-driven promotion of an experimental procedure were substantially true.
COVID-19 aged care class actions ramp back up as criminal trial nears
After more than a year on ice, two class actions against age care facilities over COVID-19 outbreaks are set to resume late this year, following a month-long criminal trial that kicks off next week. 
Ashurst’s failure to register client’s $51M interest over Infinity pharmacies an ‘oversight’: court
A junior Ashurst lawyer's failure to register a drug wholesaler's $51 million security interest over a group of Infinity pharmacies was inadvertent, a judge has found in granting a bid to extend the deadline for registration.
IVF provider Genea faces class action investigation over data breach
Fertility services provider Genea is facing a class action investigation over a data breach that led to sensitive patient information being published on the dark web.
Celebrity surgeon loses defamation suit against Nine
A court has ruled that media reports accusing well-known orthopaedic surgeon Dr Munjed Al Muderis of unethical and profit-driven promotion of an experimental procedure were substantially true, tossing his defamation suit against Fairfax and its owner Nine.  
Novartis’ last ditch bid to block Entresto generic fails
The High Court has rejected Novartis' plea that it overturn a ruling that found an extension of the term of the patent for its heart drug Entresto was invalidly granted.
Trial over Cosette’s termination of $672M Mayne Pharma merger delayed
Mayne Pharma and US drug maker Cosette have agreed to postpone the start of trial in a case over the termination of a $672 million merger to allow for late amendments.
Mayne denies continuous disclosure breaches in feud with Cosette
Mayne Pharma has denied US drug maker Cosette's claims it breached its continuous disclosure obligations in relation to US FDA concerns about marketing for its Nextstellis contraceptive, as the drug makers spar over their $672 million merger.
Oxford Nanopore brings patent infringement case against MGI
Genomic sequencing company Oxford Nanopore Technologies has sued MGI Australia alleging infringement of four patents covering nanopore technology.
Attacked as untenable, Bupa class action faces potential summary dismissal bid
A class action against aged care provider Bupa faced tough questions by a judge on Monday, who grilled counsel over the case's theory of loss. And the answers — rather than reassuring her — raised the spectre of a summary judgment fight.